Atossa Therapeutics has strong financials with $79.5 million in cash and a cash runway of 13-14 quarters, minimizing ...

Inhibition of CDK6 may prevent arteriovenous malformations in hereditary hemorrhagic telangiectasia by regulating endothelial ...

A nurse practitioner discusses ASCO’s recommendations of CDK4/6 inhibitors—namely abemaciclib and ribociclib—in certain high-risk breast cancer settings.

Abemaciclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, in the same class as Pfizer's Ibrance (palbociclib) which was granted accelerated approval by the US FDA as a first-line therapy ...

Tango Therapeutics (NASDAQ:TNGX) stock plunged 28% in morning trading Wednesday after the company announced updates on ...

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the ...

This has included hormone suppression with an aromatase inhibitor and taking Verzenio, which is the Eli Lilly and Company brand name for abemaciclib. Abemaciclib targets certain proteins in cancer ...

Significant Ki-67 protein suppression in HR-positive, HER2-negative breast cancer was seen among patients treated with ...

POETIC-A is investigating whether adding the drug abemaciclib alongside hormone therapy can help prevent higher risk early breast cancer from returning. Abemaciclib works by blocking molecules which ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

Tango Therapeutics (TNGX) announced an update on its PRMT5 program. Based on data from the dose escalation and early dose expansion cohorts of ...

HR+ HER2-ve Breast Cancer Therapies- TQB3616 capsule, NTQ1062 with Fulvestrant, Pembrolizumab, Sacituzumab Govitecan, ...